logo
Twitter
Discord
Email
logo
Exact Sciences Corporation

Exact Sciences Corporation

NASDAQ•EXAS
CEO: Mr. Kevin T. Conroy J.D.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 2001-02-01
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Contact Information
5505 Endeavor Lane, Madison, WI, 53719, United States
608-284-5700
www.exactsciences.com
Market Cap
$19.16B
P/E (TTM)
-19.4
26.3
Dividend Yield
--
52W High
$101.87
52W Low
$38.81
52W Range
99%
Rank67Top 91.5%
1.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$850.74M+20.05%
4-Quarter Trend

EPS

-$0.10-52.38%
4-Quarter Trend

FCF

$190.03M+68.82%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Revenue Growth Strong Nine months revenue reached $2.37B, showing 15.8% increase driven by Cologuard volume growth and new launches.
Operating Cash Flow Surge Cash provided by operations totaled $339.7M for nine months, improving $176.3M versus prior year period results.
Net Loss Significantly Reduced Nine months net loss narrowed to $(122.0M) compared to $(164.3M) loss last year, indicating improved performance.
New Product Launches Complete Launched Cologuard Plus in March 2025 and Cancerguard in September 2025, expanding screening portfolio access.

Risk Factors

Ongoing Profitability Concerns Accumulated deficit reached $4.62B as of September 30, 2025; sustained profitability remains uncertain despite improvements.
Productivity Plan Costs Incurred $72.6M in restructuring and business transformation charges through September 30, 2025 period for efficiency efforts.
FDA Review Delays Risk Government shutdowns or policy changes may slow FDA review, potentially delaying new product approvals impacting operations.
Contingent Consideration Valuation Contingent consideration liability stands at $284.1M, valued using Level 3 unobservable inputs requiring management judgment.

Outlook

Productivity Plan Savings Goal Multi-year plan aims for over $150.0M in expected annual savings by 2026 via general and administrative efficiencies.
Pipeline Advancement Focus Prioritize launching Cologuard Plus, Oncodetect, and Cancerguard tests while investing in clinical trial enhancements.
Credit Facility Available Secured $500.0M Revolving Credit Facility in January 2025; no funds drawn as of September 30, 2025.
Continuing Revenue Growth Expected Expect revenue growth for Cologuard and Oncotype tests, subject to seasonality, payer mix, and new product adoption.

Peer Comparison

Revenue (TTM)

Viatris Inc.VTRS
$14.12B
-6.1%
Baxter International Inc.BAX
$11.02B
-6.3%
Illumina, Inc.ILMN
$4.29B
-2.3%

Gross Margin (Latest Quarter)

Ionis Pharmaceuticals, Inc.IONS
98.5%
-0.7pp
BridgeBio Pharma, Inc.BBIO
94.6%
+16.5pp
Roivant Sciences Ltd.ROIV
92.9%
-1.8pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
ILMN$19.56B28.430.0%41.7%
EXAS$19.16B-19.4-40.4%42.7%
ROIV$14.73B-38.6-8.0%2.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
6.0%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 3, 2025|
    Revenue: $850.74M+20.1%
    |
    EPS: $-0.10-52.4%
    Miss

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 6, 2025|
    Revenue: $811.09M+16.0%
    |
    EPS: $-0.01-92.7%
    Beat

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 1, 2025|
    Revenue: $706.79M+10.9%
    |
    EPS: $-0.54-10.0%
    Miss

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 19, 2025|
    Revenue: $2.76B+10.4%
    |
    EPS: $-5.59-394.7%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 5, 2024|
    Revenue: $708.66M+12.8%
    |
    EPS: $-0.21-4872.7%
    Miss

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 31, 2024|
    Revenue: $699.26M+12.4%
    |
    EPS: $-0.09-80.9%
    Beat

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $637.52M+5.8%
    |
    EPS: $-0.60+42.9%
    Miss

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 21, 2024|
    Revenue: $2.50B+19.9%
    |
    EPS: $-1.13+68.1%
    Miss